Pfizer's stock just reached its highest point in a year. What’s happening?

Oct 15, 2026, 12:10 PM ETTrialRead the original at Benzinga

Good for PFE

Pfizer's approved treatment plan gives some people with advanced breast cancer another maintenance option, and trial patients went longer before their disease worsened. Drugmakers also rose broadly, and the approval was reported earlier, but the patient results and added treatment use favor Pfizer.

PFE · Pfizer Inc

AI read · Good for PFE

The AI's read

The added treatment option may help Pfizer reach more people with advanced HER2-positive breast cancer. In the trial, patients went 24.9 months before their disease worsened, versus 16.3 months with placebo. That result supports the treatment, but the article gives no sales estimate. Drugmakers rose broadly, and Pfizer's approval was already reported, so the share rise cannot be credited to Pfizer's news alone.

Get alerts for PFE

Follow Pfizer Inc (PFE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PFE

Free on the App Store and Google Play, or on the web.